DRG Epidemiology's coverage of BPH comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of BPH for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report.

DRG Epidemiology's BPH forecast will answer the following questions:

  • Of all people with BPH, how many in each country across the major mature pharmaceutical markets have been formally diagnosed?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of BPH over the forecast period?

All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

In addition to the total number of cases for each forecast year, DRG Epidemiology also provides at least ten years of forecast data for the following BPH subpopulations:

  • Total prevalent cases by diagnosis status

Note: coverage may vary by country.

Table of contents

  • Benign Prostatic Hyperplasia - Epidemiology - Mature Markets
    • Introduction
      • Key Findings
      • Total Prevalence of Benign Prostatic Hyperplasia per 1,000 Among Males Aged 40+ in 2018 and 2038
      • Relative Sizes of the Factors Contributing to the Trend in Total Prevalent Cases of Benign Prostatic Hyperplasia over the Next Twenty Years
    • Epidemiology Data
    • Methods
      • Total Incident Cases
      • Total Prevalent Cases of Benign Prostatic Hyperplasia
      • Diagnosed Prevalent Cases of Benign Prostatic Hyperplasia
      • Lifetime DALYs Gained
    • Reference Materials
      • Literature Review
        • Studies Included in the Analysis of Benign Prostatic Hyperplasia
        • Studies Excluded from the Analysis of Benign Prostatic Hyperplasia
      • Risk/Protective Factors
        • Risk/Protective Factors for Benign Prostatic Hyperplasia
      • Bibliography

Author(s): Stephanie Niquita; Abey John, MPH

Stephanie Niquita works as an associate epidemiologist at Decision Resources Group. Stephanie holds a masters in public health specializing in epidemiology from TISS, Mumbai and a medical degree from Hubei University of Chinese Medicine, People’s Republic of China. She has been trained as a community physician and has also supervised and coordinated various governmental and non-governmental public health projects.

Abey John is a medical graduate with a Master’s in Public Health and has been associated with DRG since September 2015. He works with a global team of epidemiologists in performing systematic reviews of assigned diseases and prepare forecast models for clients. He also is involved in producing analyses for pharmaceutical drug developers on the descriptive epidemiology of major drug indications in mature and developing markets and have an overall experience of three years working in different healthcare sectors across the country.

Prior to joining DRG, Abey had been working with Jhpiego (an affiliate of Johns Hopkins Medical University) in implementing Family Planning Health Programs in India with collaborating with the Government of India. He also has worked with a grassroots level NGO as a health team manager which worked for the benefit of the rural population living in the foothills of the Himalayas.